CHEMISCHE MITTEL
PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tum...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TAYLORSON, CHRISTOPHER JOHN HEATON, WILLIAM TARRAGONA-FIOL, ANTONIO BLAKEY, CHARLES HENNEQUIN, FRANCOIS RABIN, ROBERT SLATER, MICHAEL EGGELTE, JOHANNES BOYLE, THOMAS HENNAM, FREDERICK MARSHAM, ROBERT DAVIES, HUW |
| description | PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DE69527805TT2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DE69527805TT2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DE69527805TT23</originalsourceid><addsrcrecordid>eNrjZBBw9nD19QwGkgq-niEhrj48DKxpiTnFqbxQmptByc01xNlDN7UgPz61uCAxOTUvtSTexdXM0tTI3MLANCTEyJgoRQA_cR5H</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CHEMISCHE MITTEL</title><source>esp@cenet</source><creator>TAYLORSON, CHRISTOPHER JOHN ; HEATON, WILLIAM ; TARRAGONA-FIOL, ANTONIO ; BLAKEY, CHARLES ; HENNEQUIN, FRANCOIS ; RABIN, ROBERT ; SLATER, MICHAEL ; EGGELTE, JOHANNES ; BOYLE, THOMAS ; HENNAM, FREDERICK ; MARSHAM, ROBERT ; DAVIES, HUW</creator><creatorcontrib>TAYLORSON, CHRISTOPHER JOHN ; HEATON, WILLIAM ; TARRAGONA-FIOL, ANTONIO ; BLAKEY, CHARLES ; HENNEQUIN, FRANCOIS ; RABIN, ROBERT ; SLATER, MICHAEL ; EGGELTE, JOHANNES ; BOYLE, THOMAS ; HENNAM, FREDERICK ; MARSHAM, ROBERT ; DAVIES, HUW</creatorcontrib><description>PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.</description><edition>7</edition><language>ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; DERIVATIVES THEREOF ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROCESSES USING MICROORGANISMS ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; SUGARS ; VINEGAR ; WINE</subject><creationdate>2003</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20030424&DB=EPODOC&CC=DE&NR=69527805T2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20030424&DB=EPODOC&CC=DE&NR=69527805T2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TAYLORSON, CHRISTOPHER JOHN</creatorcontrib><creatorcontrib>HEATON, WILLIAM</creatorcontrib><creatorcontrib>TARRAGONA-FIOL, ANTONIO</creatorcontrib><creatorcontrib>BLAKEY, CHARLES</creatorcontrib><creatorcontrib>HENNEQUIN, FRANCOIS</creatorcontrib><creatorcontrib>RABIN, ROBERT</creatorcontrib><creatorcontrib>SLATER, MICHAEL</creatorcontrib><creatorcontrib>EGGELTE, JOHANNES</creatorcontrib><creatorcontrib>BOYLE, THOMAS</creatorcontrib><creatorcontrib>HENNAM, FREDERICK</creatorcontrib><creatorcontrib>MARSHAM, ROBERT</creatorcontrib><creatorcontrib>DAVIES, HUW</creatorcontrib><title>CHEMISCHE MITTEL</title><description>PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>DERIVATIVES THEREOF</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROCESSES USING MICROORGANISMS</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>SUGARS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2003</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBBw9nD19QwGkgq-niEhrj48DKxpiTnFqbxQmptByc01xNlDN7UgPz61uCAxOTUvtSTexdXM0tTI3MLANCTEyJgoRQA_cR5H</recordid><startdate>20030424</startdate><enddate>20030424</enddate><creator>TAYLORSON, CHRISTOPHER JOHN</creator><creator>HEATON, WILLIAM</creator><creator>TARRAGONA-FIOL, ANTONIO</creator><creator>BLAKEY, CHARLES</creator><creator>HENNEQUIN, FRANCOIS</creator><creator>RABIN, ROBERT</creator><creator>SLATER, MICHAEL</creator><creator>EGGELTE, JOHANNES</creator><creator>BOYLE, THOMAS</creator><creator>HENNAM, FREDERICK</creator><creator>MARSHAM, ROBERT</creator><creator>DAVIES, HUW</creator><scope>EVB</scope></search><sort><creationdate>20030424</creationdate><title>CHEMISCHE MITTEL</title><author>TAYLORSON, CHRISTOPHER JOHN ; HEATON, WILLIAM ; TARRAGONA-FIOL, ANTONIO ; BLAKEY, CHARLES ; HENNEQUIN, FRANCOIS ; RABIN, ROBERT ; SLATER, MICHAEL ; EGGELTE, JOHANNES ; BOYLE, THOMAS ; HENNAM, FREDERICK ; MARSHAM, ROBERT ; DAVIES, HUW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DE69527805TT23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2003</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>DERIVATIVES THEREOF</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROCESSES USING MICROORGANISMS</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>SUGARS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>TAYLORSON, CHRISTOPHER JOHN</creatorcontrib><creatorcontrib>HEATON, WILLIAM</creatorcontrib><creatorcontrib>TARRAGONA-FIOL, ANTONIO</creatorcontrib><creatorcontrib>BLAKEY, CHARLES</creatorcontrib><creatorcontrib>HENNEQUIN, FRANCOIS</creatorcontrib><creatorcontrib>RABIN, ROBERT</creatorcontrib><creatorcontrib>SLATER, MICHAEL</creatorcontrib><creatorcontrib>EGGELTE, JOHANNES</creatorcontrib><creatorcontrib>BOYLE, THOMAS</creatorcontrib><creatorcontrib>HENNAM, FREDERICK</creatorcontrib><creatorcontrib>MARSHAM, ROBERT</creatorcontrib><creatorcontrib>DAVIES, HUW</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TAYLORSON, CHRISTOPHER JOHN</au><au>HEATON, WILLIAM</au><au>TARRAGONA-FIOL, ANTONIO</au><au>BLAKEY, CHARLES</au><au>HENNEQUIN, FRANCOIS</au><au>RABIN, ROBERT</au><au>SLATER, MICHAEL</au><au>EGGELTE, JOHANNES</au><au>BOYLE, THOMAS</au><au>HENNAM, FREDERICK</au><au>MARSHAM, ROBERT</au><au>DAVIES, HUW</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CHEMISCHE MITTEL</title><date>2003-04-24</date><risdate>2003</risdate><abstract>PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | ger |
| recordid | cdi_epo_espacenet_DE69527805TT2 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS SUGARS VINEGAR WINE |
| title | CHEMISCHE MITTEL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T01%3A00%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TAYLORSON,%20CHRISTOPHER%20JOHN&rft.date=2003-04-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDE69527805TT2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |